Stay updated with breaking news from Daniel Spratt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Despite growing enthusiasm for this minimally invasive option for some men with prostate cancer, focal therapy is still not FDA-approved for prostate cancer and comes with high out-of-pocket costs.
ArteraAI intended to improve risk stratification or prognostication over standard clinical and pathologic tools and spare men unnecessary treatment.
It's recommended that you consider getting screened once you reach your 40s, which gives you the best chance of getting treated early.
Improved toxicity, advanced technology, and novel techniques have helped increase the use of radiotherapy for the treatment of different subgroups of patients with prostate cancer.
Daniel Spratt, MD, discusses research findings that have delineated the optimal sequencing of radiation therapy and hormone therapy for patients with prostate cancer.